Dyadic's c1 platform selected by the vaccine and immunotherapy center (“vic”) at massachusetts general hospital as part of vic's $5.88 million award by u.s. dod to develop a self-assembling vaccine (sav) platform for rapid production of prophylactic vaccines for infectious diseases

Jupiter, fla., oct. 05, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the vaccine and immunotherapy center (“vic”) at massachusetts general hospital, as part of vic's collaboration with voltron therapeutics, inc. (“voltron”), to use dyadic's proprietary c1 protein production platform to express vaccine antigens for influenza a and other infectious diseases.
DYAI Ratings Summary
DYAI Quant Ranking